Search

Genmab A-S

Cerrado

1,915.5 3.43

Resumen

Variación precio

24h

Actual

Mínimo

1822

Máximo

1866

Métricas clave

By Trading Economics

Ingresos

21M

52M

Ventas

-169M

896M

P/B

Media del Sector

21.345

62.58

BPA

8.48

Margen de beneficios

5.818

Empleados

3,088

EBITDA

-30M

215M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-1.49% downside

Dividendos

By Acuity

Próximas Ganancias

6 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

8.6B

113B

Apertura anterior

1912.07

Cierre anterior

1915.5

Genmab A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 23:56 UTC

Fair Isaac Corp shares are higher in after-market trading, supported by positive investor sentiment and a notable rise in the Nikkei 225 Index.

21 jul 2026, 23:56 UTC

Ulta Beauty Inc. shares are lower in after-market trading, reflecting broader market trends despite positive sentiment from the Nikkei 225 Index surge.

21 jul 2026, 23:56 UTC

American Electric Power shares are lower in after-market hours, continuing a three-session decline and remaining below the 20-day moving average.

21 jul 2026, 23:56 UTC

Mondelez International shares declined in after-market trading, continuing a trend of four consecutive lower daily closes despite earlier gains during the session.

21 jul 2026, 23:56 UTC

Northern Trust shares are higher in after-market trading, reflecting broader positive trends in regional equity indices and renewed investor optimism.

21 jul 2026, 23:56 UTC

Dorian LPG Ltd shares are trading higher in after-market hours, reflecting a gradual increase since Tuesday's close amid broader positive trends in regional equity indices.

21 jul 2026, 23:56 UTC

Macro News
ETF Constituents
Correlated Moves

U.S. stock markets rebounded, with the Financial Select Sector SPDR Fund roughly flat in after-hours trading, supported by contributions from SCHW, ICE, FISV, AON, and AXP.

21 jul 2026, 23:56 UTC

No specific news was identified for Alnylam Pharmaceuticals during after-market hours. The stock remains near unchanged since Tuesday's close.

21 jul 2026, 23:56 UTC

Phillips 66 shares are higher in after-market trading, with no specific news identified. Broader market momentum reflects positive investor sentiment amid easing geopolitical tensions.

21 jul 2026, 23:56 UTC

Shake Shack Inc. shares are higher in after-market trading, reflecting a modest gain amid positive sentiment from broader market trends, including a rise in the Nikkei 225 Index.

21 jul 2026, 23:56 UTC

Diamondback Energy Inc shares are lower in after-market hours, continuing a decline since Tuesday's close. Trading has reflected overall weaker performance without specific news.

21 jul 2026, 23:56 UTC

Lumen Technologies Inc. shares are higher in after-market hours, reflecting a modest gain amid broader market weakness and positive sentiment in regional equity indices.

21 jul 2026, 23:56 UTC

Baidu Inc. shares declined in after-market trading, retracing from an early session peak and remaining below recent averages. No specific news was identified.

21 jul 2026, 23:56 UTC

Southern Copper Corp shares are lower in after-market trading, retracing from earlier gains while remaining above their 20-day moving average.

21 jul 2026, 23:56 UTC

Entegris Inc shares are higher in after-market trading, reflecting a notable gain since Tuesday's close amid positive sentiment in regional equity indices.

21 jul 2026, 23:56 UTC

ETF Constituents

Health Care Select Sector SPDR Fund declines after market close, driven by negative returns from Merck, Amgen, and Eli Lilly. The ETF remains near its one-month trading range.

21 jul 2026, 23:52 UTC

Kratos Defense shares are higher in after-market trading, rebounding from earlier losses despite no specific news to explain the movement.

21 jul 2026, 23:51 UTC

Japan's Trade Deficit Expected at -120 Billion Yen Amid Ongoing Economic Challenges and Investor Caution.

21 jul 2026, 23:51 UTC

Japan's June export growth forecasted at 0.186%, crucial for GDP amid stable market expectations and global supply chain challenges.

21 jul 2026, 23:51 UTC

Brazil's Central Bank Signals Potential Interest Rate Cuts Amid Lower Inflation Expectations Ahead of Key COPOM Meeting on July 27, 2026.

21 jul 2026, 23:51 UTC

iShares Core U.S. Aggregate Bond ETF is trading higher in after-market hours amid a general upward trend in global equity indices and positive sentiment in fixed income.

21 jul 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

21 jul 2026, 23:51 UTC

Yum China Holdings Inc. shares rose in after-market trading, buoyed by positive market sentiment following earnings reports from Tesla and Broadcom.

21 jul 2026, 23:51 UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

21 jul 2026, 23:51 UTC

Zeta Global Holdings is higher in after-market trading, amid broader market strength following positive earnings from companies like Tesla and Broadcom.

21 jul 2026, 23:51 UTC

Intercontinental Exchange Inc shares are higher in after-market hours amid increased trading activity, remaining above their 20-day moving average and near a one-month high.

21 jul 2026, 23:51 UTC

Coca-Cola Europacific Partners PLC shares are lower in after-market hours amid notable volatility, with no specific company news identified to explain the movement.

21 jul 2026, 23:51 UTC

Starwood Property Trust shares rose in after-market trading amid positive market sentiment following earnings reports from companies like Tesla and Broadcom.

21 jul 2026, 23:51 UTC

NetEase Inc. shares are higher in after-market trading, reflecting positive sentiment from recent earnings reports of firms like Tesla and Broadcom.

21 jul 2026, 23:51 UTC

Correlated Moves

Nexgen Energy Ltd shares advanced in after-market trading, buoyed by positive sentiment following earnings reports from major companies like Tesla and Broadcom.

Comparación entre iguales

Cambio de precio

Genmab A-S previsión

Precio Objetivo

By TipRanks

-1.49% descenso

Estimación a 12 Meses

Media 2,493.35 DKK  -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genmab A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

3

Comprar

2

Mantener

2

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.